Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
- PMID: 28469716
- PMCID: PMC5399694
- DOI: 10.4103/atm.ATM_231_16
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder that often occurs in patients with asthma or cystic fibrosis (CF) and is characterized by a hypersensitivity response to the allergens of the fungus Aspergillus fumigatus. In patients with CF, growth of A. fumigatus hyphae within the bronchial lumen triggers an immunoglobulin E (IgE)-mediated hypersensitivity response that results in airway inflammation, bronchospasm, and bronchiectasis. In most published studies, the prevalence of ABPA is about 8.9% in patients with CF. Since the clinical features of this condition overlap significantly with that of CF, ABPA is challenging to diagnose and remains underdiagnosed in many patients. Diagnosis of ABPA in CF patients should be sought in those with evidence of clinical and radiologic deterioration that is not attributable to another etiology, a markedly elevated total serum IgE level (while off steroid therapy) and evidence of A. fumigatus sensitization. Management of ABPA involves the use of systemic steroids to reduce inflammation and modulate the immune response. In patients who do not respond to steroids or cannot tolerate them, antifungal agents should be used to reduce the burden of A. fumigatus allergens. Recent studies suggest that omalizumab may be an effective option to reduce the frequency of ABPA exacerbations in patients with CF. Further randomized controlled trials are needed to better establish the efficacy of omalizumab in managing patients with CF and ABPA.
Keywords: Allergic bronchopulmonary aspergillosis; allergic fungal mycosis; cystic fibrosis.
Conflict of interest statement
There are no conflicts of interest.
Figures


Similar articles
-
Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.Front Pediatr. 2020 Oct 20;8:582964. doi: 10.3389/fped.2020.582964. eCollection 2020. Front Pediatr. 2020. PMID: 33194914 Free PMC article. Review.
-
IgE antibody to Aspergillus fumigatus recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis.Allergy. 2004 Feb;59(2):198-203. doi: 10.1046/j.1398-9995.2003.00310.x. Allergy. 2004. PMID: 14763934
-
The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.Dev Period Med. 2015 Jan-Mar;19(1):66-79. Dev Period Med. 2015. PMID: 26003072
-
Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy.Eur J Immunol. 1998 Apr;28(4):1155-60. doi: 10.1002/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.0.CO;2-6. Eur J Immunol. 1998. PMID: 9565354
-
Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review.Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620961648. doi: 10.1177/1753466620961648. Ther Adv Respir Dis. 2020. PMID: 33050821 Free PMC article. Review.
Cited by
-
Fungal Infection and Inflammation in Cystic Fibrosis.Pathogens. 2021 May 18;10(5):618. doi: 10.3390/pathogens10050618. Pathogens. 2021. PMID: 34069863 Free PMC article. Review.
-
Approaching two decades of cystic fibrosis research in Qatar: a historical perspective and future directions.Multidiscip Respir Med. 2019 Oct 1;14:29. doi: 10.1186/s40248-019-0193-4. eCollection 2019. Multidiscip Respir Med. 2019. PMID: 31583102 Free PMC article. Review.
-
Pathogenicity and virulence of Aspergillus fumigatus.Virulence. 2023 Dec;14(1):2172264. doi: 10.1080/21505594.2023.2172264. Virulence. 2023. PMID: 36752587 Free PMC article. Review.
-
A Peculiar Case of Pneumonia due to Mycoplasma pneumoniae in a Child with Cystic Fibrosis and Sensibilization to Aspergillus fumigatus.Pathogens. 2019 Dec 22;9(1):15. doi: 10.3390/pathogens9010015. Pathogens. 2019. PMID: 31877884 Free PMC article.
-
Pediatric usage of Omalizumab: A promising one.World Allergy Organ J. 2021 Dec 11;14(12):100614. doi: 10.1016/j.waojou.2021.100614. eCollection 2021 Dec. World Allergy Organ J. 2021. PMID: 34963793 Free PMC article. Review.
References
-
- Strausbaugh SD, Davis PB. Cystic fibrosis: A review of epidemiology and pathobiology. Clin Chest Med. 2007;28:279–88. - PubMed
-
- Riordan JR. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol. 1993;55:609–30. - PubMed
-
- Sheppard MN, Nicholson AG. The pathology of cystic fibrosis. Curr Diagn Pathol. 2002;8:50–9.
-
- Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. Clin Chest Med. 2012;33:265–81. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources